The Journal of Nuclear Medicine (JNM)90Y Radioembolization in the Treatment of Neuroendocrine Neoplasms: Results of an International Multicenter Retrospective Study

In patients with NETs with distant metastasis, ⁹⁰Y radioembolization (⁹⁰Y RE) might be an important treatment option; however, data to support clinical benefits are scarce. The authors purposed to analyze the use of ⁹⁰Y RE in NET patients with hepatic metastases in an international, multicenter retrospective analysis. In reviewing response data, they conclude that ⁹⁰Y RE could be an important alternative to peptide receptor radionuclide therapy as second-line treatment in patients with progressive liver-dominant disease pretreated with somatostatin analogs.